Immunotherapy in Thymic Epithelial Tumors -- ' Risky Business ' ? Immunotherapy in Thymic Epithelial Tumors -- ' Risky Business ' ?

Pembrolizumab showed encouraging antitumor activity in patients with advanced thymic epithelial tumors, but also a high rate of severe immune-related adverse events.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news